Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.